Drilldown: Medicines

Choose a table:

Medicines (732)

Medicines > duration

: 24 hours (HS dosing)

or 6-12 hours

or Variable

Use the filters below to narrow your results.

Amitriptyline (hydrochloride) (1) · Calcium (carbonate, citrate, gluconate, chloride salts) (1) · Doxepin (hydrochloride) (1) · Famotidine (1) · Hydrochlorothiazide (1) · Ivermectin (1) · Magnesium (oxide, citrate, sulfate, hydroxide, gluconate, chloride salts) (1) · Mirtazapine (1) · Nortriptyline (hydrochloride) (1)

Elavil (US brand discontinued; generic widely available), Endep, Tryptizol (1) · Mag-Ox, Slow-Mag, MagCitrate, Milk of Magnesia (hydroxide); IV sulfate generic (1) · Microzide; mostly prescribed generically (1) · Pamelor (US brand discontinued; generic widely available), Aventyl (1) · Pepcid, Pepcid AC, Pepcid Complete (1) · Remeron (US brand discontinued; generic widely available), Remeron SolTab (ODT) (1) · Sinequan (oral antidepressant, US brand discontinued), Silenor (low-dose for insomnia), Prudoxin / Zonalon (topical cream) (1) · Stromectol (oral, generic), Sklice (lice, topical), Soolantra (rosacea, topical 1%) (1) · Tums, Caltrate, Os-Cal, Citracal; many generics (1)

None (5) · '"`UNIQ--vote-00000019-QINU`"' Therapeutic plasma-level monitoring is standard practice for TCAs given the narrow therapeutic index and the established plasma-level-efficacy correlation. CYP2D6 substrate; CPIC PGx guidance applies for dose individualization'"`UNIQ--ref-0000001A-QINU`"'. (1) · '"`UNIQ--vote-00000138-QINU`"' Decreases urinary calcium (used in stone prevention); raises serum uric acid, glucose, and lipids modestly; non-anion-gap hypokalemic metabolic alkalosis is the characteristic electrolyte pattern'"`UNIQ--ref-00000139-QINU`"'. (1) · '"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1) · '"`UNIQ--vote-00001302-QINU`"' Renally cleared; accumulation in advanced CKD can produce neuromuscular and cardiac depression. Hypomagnesemia frequently co-exists with hypokalemia and is often the reason refractory potassium loss does not correct until magnesium is repleted. (1)

12.5-25 mg PO once daily (1) · 15 mg PO at bedtime, titrate to 30-45 mg/day after 1-2 weeks. '''Counterintuitive dose paradox''': lower doses (7.5-15 mg) are more sedating than higher doses because H1 antihistamine effect dominates at low dose (1) · 20 mg PO twice daily, or 40 mg at bedtime (1) · Depression (rarely used now): 25-75 mg PO at bedtime, titrate to 150 mg/day. Neuropathic pain / migraine prophylaxis: 10-25 mg at bedtime, titrate by 10-25 mg weekly to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions apply) (1) · Depression: 25 mg PO TID-QID or 75 mg at bedtime, titrate to 75-150 mg/day. Neuropathic pain: 10-25 mg at bedtime, titrate to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions, though less than amitriptyline) (1) · Depression: 25-75 mg/day to start, titrate to 75-150 mg/day at bedtime. Insomnia (Silenor): 3 mg PO 30 minutes before bedtime, max 6 mg. Topical (Prudoxin): apply to affected area every 3-4 hours (1) · Oral: 1000-1500 mg elemental calcium/day in divided doses for supplementation; IV gluconate 1 g (4.65 mEq) over 5-10 min for hyperkalemia or symptomatic hypocalcemia (1) · Replacement oxide 400-800 mg/d in divided doses (high diarrhea rate); citrate 200-400 mg/d (better tolerated, better absorbed); IV sulfate 1-2 g over 5-60 minutes for hypomagnesemia or torsades; eclampsia 4-6 g IV loading then 1-2 g/h (1) · Strongyloides 200 mcg/kg PO single dose; scabies 200 mcg/kg PO repeated at 7-14 days; onchocerciasis 150 mcg/kg q6-12 months (1)

10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) · 12.5 mg capsules; 12.5, 25, 50 mg tablets (1) · 3 mg tablets (Stromectol); 0.5% topical lotion (Sklice); 1% topical cream (Soolantra) (1) · Capsules 10, 25, 50, 75 mg; oral solution 10 mg/5 mL (1) · Capsules 10, 25, 50, 75, 100, 150 mg; oral concentrate 10 mg/mL; Silenor tablets 3, 6 mg; topical cream 5% (Prudoxin, Zonalon) (1) · Carbonate 200, 400, 500, 600 mg elemental tablets and chewables; citrate 200, 250, 315 mg elemental; gluconate 1 g (94 mg elemental, 4.65 mEq) IV; chloride 1 g (270 mg elemental, 13.6 mEq) IV (1) · Oxide 400, 500 mg tablets (240, 300 mg elemental); citrate 100, 150, 200 mg tablets; hydroxide oral suspension 400 mg/5 mL; sulfate IV 500 mg/mL ampules (1) · Tablets 10, 25, 50, 75, 100, 150 mg (1) · Tablets 7.5, 15, 30, 45 mg; orally disintegrating tablets (SolTab) 15, 30, 45 mg (1)

150 mg/day; therapeutic plasma-level monitoring recommended (target 50-150 ng/mL window) (1) · 160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1) · 300 mg/day (depression, hospitalized); 150 mg/day outpatient; 6 mg/day for insomnia (1) · 300 mg/day (historical hospitalized inpatient depression); 150 mg/day outpatient typical ceiling (1) · 45 mg/day (1) · 50 mg/d (hypertension); up to 200 mg/d (edema) (1) · Indication-specific; renal clearance limits tolerable cumulative dosing (1) · Single 200-400 mcg/kg per dose for systemic indications (1) · ~2500 mg elemental/d combined diet + supplements (chronic; UL) (1)

IV (2) · IV (gluconate or chloride for acute use) (1) · Oral (9) · topical (2)

1 hour PO; minutes IV (1) · Acute: minutes (IV); chronic: bone effect over months (1) · Diuresis at 2 hours; antihypertensive effect within days, max at 3-4 weeks (1) · Hours to days (1) · Oral: hours; IV: minutes (1) · Pain and migraine prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks (1) · Sleep effect from first dose; analgesic and migraine-prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks (1) · Sleep effect from first dose; antidepressant effect over 1-4 weeks (2)

18-44 hours'"`UNIQ--ref-00000020-QINU`"' (1) · 2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) · 20-40 hours'"`UNIQ--ref-00000023-QINU`"' (1) · 6-15 hours'"`UNIQ--ref-0000013E-QINU`"' (1) · Amitriptyline 10-50 hours (highly variable); nortriptyline active metabolite 18-44 hours'"`UNIQ--ref-00000026-QINU`"' (1) · Not meaningfully described (electrolyte) (1) · Not meaningfully described (electrolyte; renally cleared) (1) · ~15 hours (parent); nordoxepin active metabolite ~30 hours'"`UNIQ--ref-00000020-QINU`"' (1) · ~16-18 hours'"`UNIQ--ref-00001092-QINU`"' (1)

40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) · 65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"' (1) · Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric) (1) · Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12% (1) · ~30% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~50% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~50% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~50% (oral; substantial first-pass)'"`UNIQ--ref-00000024-QINU`"' (1) · ~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"' (1)

Showing below up to 9 results in range #1 to #9.

M

N

Nortriptyline